Table 5.
Clinical outcomes according to the development of AKI or the need for RRT
| AKI (n = 101) | Non-AKI (n = 100) | Unadjusted effect estimate (95% CI) | p value | Adjusted effect estimate (95% CI)* | p value | |
|---|---|---|---|---|---|---|
| Renal outcomes | ||||||
| Cr at discharge, mg/dL | 1.00 (0.87–1.46) | 0.90 (0.72–1.00) | 0.15 (−0.05 to 0.34)a | 0.139 | 0.73 (0.22–1.24)a | 0.037 |
| Clinical outcomes | ||||||
| ICU mortality, n (%) | 21 (20.8) | 5 (5.0) | 5.00 (1.93–15.50)b | 0.002 | 2.81 (0.93–9.97)b | 0.081 |
| Hospital mortality, n (%) | 22 (21.8) | 5 (5.0) | 5.29 (2.06–16.37)b | 0.001 | 3.06 (1.01–10.94)b | 0.059 |
| 28-day mortality, n (%) | 18 (17.8) | 5 (5.0) | 3.72 (1.38–10.04)c | 0.009 | 1.72 (0.62–4.78)c | 0.301 |
| 60-day mortality, n (%) | 24 (23.8) | 5 (5.0) | 5.11 (1.95–13.40)c | <0.001 | 2.79 (1.04–7.49)c | 0.04 |
| Duration of ventilation in survivors, days | 10.5 (6.5–16.8) | 6.0 (3.0–9.0) | 5.22 (2.18–8.26)a | <0.001 | 6.52 (1.60–11.44)a | 0.009 |
| ICU length of stay, days | 13.5 (5.2–25.0) | 5.0 (3.0–8.0) | 0.36 (0.26–0.51)d | <0.001 | 0.44 (0.31–0.62)d | <0.001 |
| Hospital length of stay, days | 18.0 (12.8–32.2) | 10.0 (6.5–14.0) | 0.31 (0.22–0.44)d | <0.001 | 0.38 (0.27–0.55)d | <0.001 |
| RRT (n = 34) | Non-RRT (n = 166) | Unadjusted effect estimate (95% CI) | p value | Adjusted effect estimate (95% CI)* | p value | |
|---|---|---|---|---|---|---|
| Renal outcomes | ||||||
| Cr at discharge, mg/dL | 3.50 (2.00–4.34) | 0.90 (0.77–1.06) | 2.53 (0.94–4.11)a | 0.002 | 2.53 (1.02–4.05)a | 0.001 |
| RRT at hospital discharge | 1/9 (11.1) | − | − | − | − | − |
| Clinical outcomes | ||||||
| ICU mortality, n (%) | 12 (35.3) | 14 (8.4) | 5.92 (2.41–14.54)b | <0.001 | 4.39 (1.56–12.49)b | 0.005 |
| Hospital mortality, n (%) | 12 (35.3) | 15 (9.0) | 5.49 (2.25–13.32)b | <0.001 | 3.98 (1.42–11.15)b | 0.008 |
| 28-day mortality, n (%) | 7 (20.6) | 16 (9.6) | 2.27 (0.93–5.51)c | 0.071 | 1.11 (0.41–2.96)c | 0.836 |
| 60-day mortality, n (%) | 12 (35.3) | 17 (10.2) | 3.75 (1.79–7.85)c | <0.001 | 2.21 (1.01–4.85)c | 0.047 |
| Duration of ventilation in survivors, days | 17.0 (11.8–36.8) | 6.0 (4.5–11.0) | 12.78 (2.72–22.83)a | 0.012 | 12.91 (6.67–19.15)a | <0.001 |
| ICU length of stay, days | 29.0 (19.5–37.0) | 6.0 (3.0–11.0) | 0.23 (0.15–0.35)d | <0.001 | 0.26 (0.17–0.40)d | <0.001 |
| Hospital length of stay, days | 33.0 (30.0–40.0) | 12.0 (8.0–17.0) | 0.20 (0.12–0.35)d | <0.001 | 0.20 (0.12–0.35)d | <0.001 |
Data are presented as median (quartile 25%–quartile 75%) or n (%). Percentages may not total 100 because of rounding. CI, confidence interval; AKI, acute kidney injury; ICU, intensive care unit; RRT, renal replacement therapy.
*
All models are adjusted by SAPS3 and Charlson Comorbidity Index.
a
Effect estimate is median difference from a quantile regression with T = 0.50 and results estimated with bootstrap with 1,000 resamples.
b
Effect estimate is odds ratio from a generalized linear model with a binomial distribution.
c
Effect estimate is hazard ratio from a Cox proportional hazard model.
d
Effect estimate is subdistribution hazard ratio from a Fine-Gray competing risk model.